Pfizer gets new rebuff from NICE for cancer drug
LONDON (Reuters) - Pfizer suffered a second rejection in two days from health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
- Tweet this
- Share this
- Digg this
- Canada's parliament attacked, soldier fatally shot nearby |
- Hungary plans new tax on Internet traffic, public calls for rally
- Some U.S. hospitals weigh withholding care to Ebola patients
- UPDATE 1-Tennis-WTA Finals women's singles round robin red group results
- NATO, Swedish fighters scrambled to intercept Russian plane